An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type 1 diabetes, hepatitis ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage ...

Investing.com -- Contineum Therapeutics Inc (NASDAQ: CTNM) stock fell 8.4% after the clinical-stage biopharmaceutical company announced a delay in reporting topline data from its Phase 1b trial of ...

ARGX-119 in congenital myasthenic syndromes: Amsterdam, the Netherlands Tuesday, July 1, 2025, 18:00 Hrs [IST] argenx SE, a global immunolo ...

Birmingham has a very strong history of immunology research going back 30 years, and with one of the greatest concentrations of scientists and doctors in the world is well positioned to make a ...

US biotech fund BVF Parners has sold its stake in drug developer Syntara, thus exiting all of its ASX life sciences exposures ...

Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduct ...

The impact of oxidative stress on symptoms associated with multiple sclerosis Raquel Piñar-Morales Raquel Durán Francisco J. Barrero-Hernández Research Open Access 02 Jul 2025 Scientific Reports ...